Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12.
Immunomodulation using the recombinant monoclonal human B7-DC cross-linking antibody rHIgM12.
复制标题
使用重组单克隆人 B7-DC 交联抗体 rHIgM12 进行免疫调节。
DOI：
10.1111/j.1365-2249.2005.02992.x
复制
发表时间：
2006
期刊：
影响因子：
--
通讯作者：
Pease,LR
中科院分区：
文献类型：
--
作者：
VanKeulen,VP;Ciric,B;Radhakrishnan,S;Heckman,KL;Mitsunaga,Y;Iijima,K;Kita,H;Rodriguez,M;Pease,LR
A patient with Waldenstrom’s macroglobulinaemia expresses a high titre IgM antibody in serum that binds both mouse and human dendritic cells (DC) in a B7-DC (PD-L2)-dependent manner. We have reported previously that purified antibody from patient serum activates immature and mature DCin vitro, enhancing the ability of these professional antigen-presenting cells to activate naive T cells, take up antigen, resist a cytokine-depleted environment and secrete immunomodulatory cytokines, such as interkeukin (IL)-6 and tumour necrosis factor (TNF)-α. Systemic treatment of experimental animals with this antibody induces potent anti-melanoma immunity and modulates protectively the recall response against antigen challenge through the airway in an experimental model of inflammatory airway disease. Here we describe a monoclonal IgM antibody derived from this serum immunoglobulin that recapitulates each of these earlier observations, providing direct evidence that M protein from the Waldenstrom’s patient mediates these potent immunomodulatory effects. Furthermore, cell lines expressing this recombinant form of the human antibody provide the basis for developing this reagent for clinical application.
